Cargando…
Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma
Immune checkpoint inhibitor (ICI) therapy may benefit patients with advanced esophageal squamous cell carcinoma (ESCC); however, novel biomarkers are needed to help predict the response of patients to treatment. Differentially expressed immune-related genes within The Cancer Genome Atlas ESCC datase...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553461/ https://www.ncbi.nlm.nih.gov/pubmed/34722771 http://dx.doi.org/10.1155/2021/7430315 |
_version_ | 1784591588188487680 |
---|---|
author | Ji, Qinghua Cai, Yingying Shrestha, Sachin Mulmi Shen, Duo Zhao, Wei Shi, Ruihua |
author_facet | Ji, Qinghua Cai, Yingying Shrestha, Sachin Mulmi Shen, Duo Zhao, Wei Shi, Ruihua |
author_sort | Ji, Qinghua |
collection | PubMed |
description | Immune checkpoint inhibitor (ICI) therapy may benefit patients with advanced esophageal squamous cell carcinoma (ESCC); however, novel biomarkers are needed to help predict the response of patients to treatment. Differentially expressed immune-related genes within The Cancer Genome Atlas ESCC dataset were selected using the weighted gene coexpression network and lasso Cox regression analyses. Based on these data, an immune-related gene prognostic index (IRGPI) was constructed. The molecular characteristics of the different IRGPI subgroups were assessed using mutation information and gene set enrichment analysis. Differences in immune cell infiltration and the response to ICI therapy and other drugs were also analyzed. Additionally, tumor and adjacent control tissues were collected from six patients with ESCC and the expression of these genes was verified using real-time quantitative polymerase chain reaction. IRGPI was designed based on CLDN1, HCAR3, FNBP1L, and BRCA2, the expression of which was confirmed in ESCC samples. The prognosis of patients in the high-IRGPI group was poor, as verified using publicly available expression data. KMT2D mutations were more common in the high-IRGPI group. Enrichment analysis revealed an active immune response, and immune infiltration assessment showed that the high-IRGPI group had an increased infiltration degree of CD8 T cells, which contributed to the improved response to ICI treatment. Collectively, these data demonstrate that IRGPI is a robust biomarker for predicting the prognosis and response to therapy of patients with ESCC. |
format | Online Article Text |
id | pubmed-8553461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-85534612021-10-29 Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma Ji, Qinghua Cai, Yingying Shrestha, Sachin Mulmi Shen, Duo Zhao, Wei Shi, Ruihua Biomed Res Int Research Article Immune checkpoint inhibitor (ICI) therapy may benefit patients with advanced esophageal squamous cell carcinoma (ESCC); however, novel biomarkers are needed to help predict the response of patients to treatment. Differentially expressed immune-related genes within The Cancer Genome Atlas ESCC dataset were selected using the weighted gene coexpression network and lasso Cox regression analyses. Based on these data, an immune-related gene prognostic index (IRGPI) was constructed. The molecular characteristics of the different IRGPI subgroups were assessed using mutation information and gene set enrichment analysis. Differences in immune cell infiltration and the response to ICI therapy and other drugs were also analyzed. Additionally, tumor and adjacent control tissues were collected from six patients with ESCC and the expression of these genes was verified using real-time quantitative polymerase chain reaction. IRGPI was designed based on CLDN1, HCAR3, FNBP1L, and BRCA2, the expression of which was confirmed in ESCC samples. The prognosis of patients in the high-IRGPI group was poor, as verified using publicly available expression data. KMT2D mutations were more common in the high-IRGPI group. Enrichment analysis revealed an active immune response, and immune infiltration assessment showed that the high-IRGPI group had an increased infiltration degree of CD8 T cells, which contributed to the improved response to ICI treatment. Collectively, these data demonstrate that IRGPI is a robust biomarker for predicting the prognosis and response to therapy of patients with ESCC. Hindawi 2021-10-21 /pmc/articles/PMC8553461/ /pubmed/34722771 http://dx.doi.org/10.1155/2021/7430315 Text en Copyright © 2021 Qinghua Ji et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ji, Qinghua Cai, Yingying Shrestha, Sachin Mulmi Shen, Duo Zhao, Wei Shi, Ruihua Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma |
title | Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma |
title_full | Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma |
title_fullStr | Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma |
title_full_unstemmed | Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma |
title_short | Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma |
title_sort | construction and validation of an immune-related gene prognostic index for esophageal squamous cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553461/ https://www.ncbi.nlm.nih.gov/pubmed/34722771 http://dx.doi.org/10.1155/2021/7430315 |
work_keys_str_mv | AT jiqinghua constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma AT caiyingying constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma AT shresthasachinmulmi constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma AT shenduo constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma AT zhaowei constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma AT shiruihua constructionandvalidationofanimmunerelatedgeneprognosticindexforesophagealsquamouscellcarcinoma |